Purinergic receptors mediate endothelial dysfunction and participate in atherosclerosis

Purinergic Signal. 2023 Mar;19(1):265-272. doi: 10.1007/s11302-021-09839-x. Epub 2022 Jan 3.

Abstract

Atherosclerosis is the main pathological basis of cardiovascular disease and involves damage to vascular endothelial cells (ECs) that results in endothelial dysfunction (ED). The vascular endothelium is the key to maintaining blood vessel health and homeostasis. ED is a complex pathological process involving inflammation, shear stress, vascular tone, adhesion of leukocytes to ECs, and platelet aggregation. The activation of P2X4, P2X7, and P2Y2 receptors regulates vascular tone in response to shear stress, while activation of the A2A, P2X4, P2X7, P2Y1, P2Y2, P2Y6, and P2Y12 receptors promotes the secretion of inflammatory cytokines. Finally, P2X1, P2Y1, and P2Y12 receptor activation regulates platelet activity. These purinergic receptors mediate ED and participate in atherosclerosis. In short, P2X4, P2X7, P2Y1, and P2Y12 receptors are potential therapeutic targets for atherosclerosis.

Keywords: Atherosclerosis; Endothelial dysfunction; P1 receptors; P2 receptors; Purinergic signaling.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis*
  • Endothelial Cells
  • Endothelium, Vascular
  • Humans
  • Receptors, Purinergic
  • Receptors, Purinergic P2*
  • Receptors, Purinergic P2Y1

Substances

  • Receptors, Purinergic P2
  • Receptors, Purinergic
  • Receptors, Purinergic P2Y1